Three Indian pharmaceutical companies have introduced generic versions of semaglutide injections following the expiration of the drug’s patent. Sun Pharma, Zydus Lifesciences, and Dr. Reddy’s Laboratories have unveiled their variants, offering more affordable options for patients managing Type 2 diabetes and obesity. Sun Pharma’s Noveltreat and Sematrinity, Zydus Lifesciences’ SEMAGLYN, MASHEMA, and ALTERME, and Dr. Reddy’s Laboratories’ Obeda are among the newly launched products.
Sun Pharma’s Noveltreat is designed for chronic weight management, with five dose strengths available, while Sematrinity targets Type 2 diabetes and comes in two dose strengths. The monthly costs for Noveltreat range from about Rs 900 to Rs 2,000, and for Sematrinity, it is between Rs 750 and Rs 1,300. Zydus Lifesciences has introduced its semaglutide injection in a reusable multi-dose pen device under the brand names SEMAGLYN, MASHEMA, and ALTERME, catering to both Type 2 diabetes and obesity at an estimated average monthly treatment cost of Rs 2,200.
Dr. Reddy’s Laboratories has launched Obeda, described as India’s first DCGI-approved generic semaglutide for Type 2 diabetes. Obeda is available in 2 mg and 4 mg pre-filled disposable pens for once-weekly use, priced at Rs 4,200 per month for both strengths. Semaglutide, a GLP-1 receptor agonist, is known globally for its effectiveness in improving glycemic control and aiding weight management.
India’s pharmaceutical exports have seen a 9.4% growth in 2024–25, reaching $30.47 billion. The industry is aiming for double-digit growth in 2026–27 with substantial government backing, as stated by the Ministry of Commerce and Industry. With the current valuation of around $60 billion, the pharmaceutical sector in India is projected to expand to $130 billion by 2030. India stands third globally in terms of the volume of medicines produced and exports pharmaceutical products to over 200 countries.
